Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991)

被引:79
作者
Espinel-Ingroff, A [1 ]
机构
[1] Virginia Commonwealth Univ, Div Infect Dis, Med Mycol Res Lab, Richmond, VA 23398 USA
关键词
D O I
10.1128/JCM.41.1.403-409.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The NCCLS M38-A document does not describe guidelines for testing caspofungin acetate (MK-0991) and other echinocandins against molds. This study evaluated the susceptibilities of 200 isolates of Aspergillus fumigatus, A. flavus, A. nidulans, A. niger, and A. terreus to caspofungin (MICs and minimum effective concentrations [MECs]) by using standard RPMI 1640 (RPMI) and antibiotic medium 3 (M3), two inoculum sizes (10(3) and 10(4) CFU/ml), and two MIC determination criteria (complete [MICs-0] and prominent growth inhibition [MICs-2]) at 24 and 48 h. Etest MICs were also determined. In general, caspofungin MIC-2 and MEC pairs were comparable with both media and inocula (geometric mean ranges of MECs and MICs, respectively, with larger inoculum: 0.12 to 0.64 mug/ml and 0.12 to 0.44 mug/ml with RPMI versus 0.04 to 0.51 mug/ml and 0.03 to 0.21 mug/ml with M3); however, MEC results were less influenced by testing conditions than MICs, especially with the larger inoculum. Overall, the agreement between caspofungin Etest MICs and broth dilution values was higher with MECs obtained with M3 (>90%) and the large inoculum than under the other testing conditions. Because RPMI is a more stable and chemically defined medium than M3, the determination at 24 h of the easier visual MECs with RPMI and the inoculum recommended in the M38-A document appears to be a suitable procedure at present for in vitro testing of caspofungin against Aspergillus spp. Future in vitro correlations with in vivo outcome of both microdilution and Etest procedures may detect more-relevant testing conditions.
引用
收藏
页码:403 / 409
页数:7
相关论文
共 36 条
  • [31] Evaluation of etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species
    Pfaller, MA
    Messer, SA
    Mills, K
    Bolmström, A
    Jones, RN
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (12) : 4387 - 4389
  • [32] Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species
    Pfaller, MA
    Messer, SA
    Mills, K
    Bolmström, A
    Jones, RN
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (11) : 3952 - 3954
  • [33] Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation
    Ribaud, P
    Chastang, C
    Latgé, JP
    Baffroy-Lafitte, L
    Parquet, N
    Devergie, A
    Espérou, H
    Sélimi, F
    Rocha, V
    Derouin, F
    Socié, G
    Gluckman, E
    [J]. CLINICAL INFECTIOUS DISEASES, 1999, 28 (02) : 322 - 330
  • [34] In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole
    Sutton, DA
    Sanche, SE
    Revankar, SG
    Fothergill, AW
    Rinaldi, MG
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (07) : 2343 - 2345
  • [35] Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds
    Szekely, A
    Johnson, EM
    Warnock, DW
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (05) : 1480 - 1483
  • [36] Invasive aspergillosis caused by Aspergillus ustus:: Case report and review
    Verweij, PE
    van den Berth, MFQ
    Rath, PM
    de Pauw, BE
    Voss, A
    Meis, JFGM
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (05) : 1606 - 1609